Meet the 10th cohort for gBETA Houston. Photo via gener8tor.com

National venture capital firm gener8tor named its 10th Houston cohort this week, which includes startups focused on innovative tableware to substitute teacher operations.

gBETA Houston offers startups and founders with a non-equity seven-week program that features intensive concierge coaching and access to a network of investors and partners. The founders will pitch their ideas on Oct. 24 at 6:30 p.m. at the Esperson Building.

"Each cohort shows us how innovation evolves and thrives," Muriel Foster, gBETA Houston director, says in a statement. "The Spring 2024 gBETA Houston cohort embodies creative brilliance and unyielding ambition."

The five companies named to gBETA were chosen based on their growth potential and investor readiness. They include:

  • BrainBuffet, an AI-powered platform that has already created over 250 courses to refine its personalized learning algorithm that builds customized courses that feature curated content, YouTube videos, quizzes, and progress tracking
  • Colorfull Plates, a tableware startup that creates durable, vibrant products that aim to streamline family meals and encourage children to try new flavors. It has generated $300,000 in revenue without outside dilutive funding.
  • The Parent Teacher Collaborative, a web- and mobile-based platform that aims to improve student outcomes by building strong collaborative partnerships, growing parent-teacher organizations and better managing school events. It's worked with five Houston-area communities and has raised over $144,000 in grant and contract funding since April 2023.
  • Kinfolk, a user-friendly mobile application that creates a digital time capsule of family traditions, memories and cultural heritage. It has over 50 beta-testing customers.
  • SubSpark, a mobile and desktop app that allows school administrators and teachers to post available openings for substitute teachers. The Houston-based LLC is currently beta-testing its apps with one Houston-area private school.

The five companies joined the spring 2024 cohort and the rest of the Houston gBETA network.

gBETA is supported by Downtown Houston, the City of Houston and the Downtown Redevelopment Authority. The program has accelerated 45 Houston companies since its launch in Houston in 2019. It was launched by a $1.25 million grant to be paid out over five years.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.